A recent study indicates that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who stop conventional lifestyle regimens.
Research printed in a prominent medical journal shows that while obese people can lose substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People using such treatments should be informed of the risk of rapid weight regain when the medication ends," stated expert Dr. Susan Jebb.
Such speed of recovery means a reversion to starting weight within about 18 months.
Comparing Treatments
The analysis, which examined 37 of trials involving over 9,000 of patients, compared the results of the injectable medications with older methods.
Scientists note that individuals who lose weight through diet and exercise typically see a slower weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Experts propose the mode of action of the drugs accounts for the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making binge eating far more likely."
A Chronic Issue?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the likelihood of weight regain, the therapy is often life-long.
This perspective is echoed by drug manufacturers, who state that the findings "emphasize the chronic character of excess weight," similar to managing conditions like high blood pressure.
User Accounts
People who have come off the medication describe a intense return of hunger.
"I experienced a switch flipping and you become ravenous," described a patient.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural modifications during therapy.
Significant Interest
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural changes.
